This event does not require registration.
Friday 28 May
12:00pm - 12:30pm
It is a long and complex road to take a Healthtech innovation to market. Between regulatory-heavy pathways, significant capital requirements, and securing market validation, there are no shortage of hurdles for Healthtech innovators. However, as one of our biggest tech subsectors, Healthtech represents a growing hotbed of opportunity for New Zealand. Join us as we discuss the challenges, the opportunities, and potential rewards of Healthtech that are well worth navigating the complex road to market.
Andrew is Callaghan Innovation’s Head of Health Technology and leads the sector team working to support New Zealand-based healthtech businesses in commercialising their R&D. Andrew represents Callaghan Innovation as part of the Consortium for Medical Device Technologies (CMDT) and sits on the steering committee of the NZ Health Research Strategy (NZHRS). Andrew spent over 16 years in the US working in complex sectors such as electromechanical devices and life sciences. He has a background in business internationalisation and the commercialisation of new technology. He's also held senior and leadership roles in major corporates, startups and IPO-focused growth businesses.
Debra is an angel investor, an early stage company director and an active mentor in the startup community. She also oversees the Kiwinet Investment Committee, deploying support into getting New Zealand's healthtech and other scientific discoveries out into the world, where they can deliver impact for our communities and our world.
Duncan is Senior Investment Manager at Brandon Capital. He has more than 20 years’ experience in technology commercialisation and is a self-confessed startup junkie. Duncan has a diverse background, having trained as a veterinarian, and later as a healthcare investor and founder. Duncan is proud to lead New Zealand operations for Brandon Capital and the MRCF, a premier life science venture capital fund.
Garth is the CEO of The Insides Company, a medical technology company providing solutions to colorectal surgeons for patients with intestinal failure resulting from bowel cancer, IBD and surgical complications.
He previously founded digital therapeutics company Adherium and led the company through to an ASX IPO. He has established operations and grown teams in New Zealand, Australia, The San Francisco Bay Area, the United Kingdom, and Europe. He is a member of the New Zealand Institute of Directors and has received education from the MIT Sloan School of Management, the UCLA Anderson School of Management, and the University of Waikato.